Clinical Development, Regulatory, and Reimbursement Review Duration of New Drugs in the US and European Countries

Simon Hediger, Camille E.G. Glaus, Stacie B. Dusetzina, Ulrich-Peter Rohr, Thomas J. Hwang, Kerstin Noelle Vokinger

Open source

DOI
10.1001/jamahealthforum.2026.2332
Published
2026-07-24
Container
JAMA Health Forum
Publisher
American Medical Association (AMA)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1001/jamahealthforum.2026.2332,
  title = {Clinical Development, Regulatory, and Reimbursement Review Duration of New Drugs in the US and European Countries},
  author = {Simon Hediger and Camille E.G. Glaus and Stacie B. Dusetzina and Ulrich-Peter Rohr and Thomas J. Hwang and Kerstin Noelle Vokinger},
  year = {2026},
  journal = {JAMA Health Forum},
  doi = {10.1001/jamahealthforum.2026.2332},
  url = {https://doi.org/10.1001/jamahealthforum.2026.2332}
}

RIS

TY  - JOUR
TI  - Clinical Development, Regulatory, and Reimbursement Review Duration of New Drugs in the US and European Countries
AU  - Simon Hediger
AU  - Camille E.G. Glaus
AU  - Stacie B. Dusetzina
AU  - Ulrich-Peter Rohr
AU  - Thomas J. Hwang
AU  - Kerstin Noelle Vokinger
PY  - 2026
JO  - JAMA Health Forum
DO  - 10.1001/jamahealthforum.2026.2332
UR  - https://doi.org/10.1001/jamahealthforum.2026.2332
ER  - 

APA

Hediger, S., Glaus, C. E., Dusetzina, S. B., Rohr, U., Hwang, T. J., & Vokinger, K. N. (2026). Clinical Development, Regulatory, and Reimbursement Review Duration of New Drugs in the US and European Countries. JAMA Health Forum. https://doi.org/10.1001/jamahealthforum.2026.2332

Source records